TB Infection/Latent TB Infection

For TB diagnosis and treatment in special situations, such as pediatric TB or patients with HIV, liver disease, or other comorbidities, also check for resources under Special Situations.

Core Curriculum on Tuberculosis: What the Clinician Should Know, 7th Edition: Chapter 4 Treatment for Latent Tuberculosis Infection

This chapter explains LTBI treatment. Centers for Disease Control and Prevention, 2021.

Testing and Treatment of Latent Tuberculosis Infection in the United States: A Clinical Guide for Health Care Providers and Public Health Programs: Section 4: Deciding Whether to Treat and Choosing a Regimen and Section 6 Monitoring and Managing Treatment

These sections of the Clinical Guide explain choosing an LTBI treatment regimen and monitoring treatment. National Society of Tuberculosis Clinicians and National Tuberculosis Coalition of America, 2025.

NTCA Provider Guidance: Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)

This guidance was designed to help clinical providers and nursing managers (1) quickly identify and answer key questions when considering whether to start a patient on the 3HP regimen; (2) assess the appropriateness of self-administered therapy of 3HP for each individual patient; (3) ensure that the correct drugs for the 3HP regimen are prescribed and provided to the patient; and (4) handle questions on side effects and adverse reactions for a patient currently on the 3HP regimen. National TB Controllers Association, 2018.

Innovations in TB Webinar Series

This monthly webinar series offers healthcare professionals the latest insights in screening, diagnosis, and treatment of TB disease and LTBI. The webinars provide updates on research developments and emerging treatment regimens for active TB and LTBI and innovative approaches to enhance patient adherence and outcomes. Mayo Clinic Center for TB.

LTBI: A Guide for Primary Healthcare Providers

This guide is intended for primary care to assist providers with LTBI diagnosis and treatment information. Centers for Disease Control and Prevention, 2024.

LTBI ASSIST

For clinicians, including those in primary care settings, this interactive online tool can be used to inform clinical decision making. The tool employs clinical scenarios to walk users through current TB guidelines and recommendations around screening, testing, monitoring, and treatment of latent TB infection (LTBI). Users can also access additional educational resources to support evidence-based care. Rutgers New Jersey Medical School Global TB Institute, 2024.

Rifamycin Drug-Drug Interactions: A Guide for Primary Care Providers Treating LTBI

This guide summarizes drug-drug interactions (DDI) between drugs commonly used in primary care and rifamycins. The 2020 Guidelines for the Treatment of LTBI from the Centers for Disease Control and Prevention include rifampin and rifapentine in preferred regimens for LTBI. Rifabutin is not included in a preferred regimen for LTBI and is included here only for reference. California Department of Public Health, Rutgers Ernest Mario School of Pharmacy, Rutgers Global Tuberculosis Institute, and the Curry International Tuberculosis Center, 2022.

Diagnosis and Treatment of LTBI in Adults

This pocket-sized card is intended for clinicians, including those in primary care settings. Using a stepwise approach, the card provides brief practical information on identifying those at risk for TB, testing, diagnosis, and treatment of LTBI in adults. Rutgers New Jersey Medical School Global TB Institute, 2021.